Bristol Myers Research Chief Exits in R&D Shake-Up
Bristol Myers Research Chief Exits in R&D Shake-Up
Bristol Myers Research Chief Exits in R&D Shake-Up
Key points
اہم نکات
मुख्य बातें
- Bristol Myers Squibb research chief Robert Plenge is leaving, and chief medical officer Cristian Massacesi will lead a unified R&D unit from January 1.
- The shake-up comes as the drugmaker faces patent expirations for its blockbusters Opdivo and Eliquis from around 2028 — Eliquis alone brought in more than $14 billion last year.
- Plenge, who joined with the $74 billion Celgene acquisition in 2019, will stay on in an advisory role through March 2027 to help with the transition.
- Bristol Myers Squibb research chief Robert Plenge is leaving, and chief medical officer Cristian Massacesi will lead a unified R&D unit from January 1.
- The shake-up comes as the drugmaker faces patent expirations for its blockbusters Opdivo and Eliquis from around 2028 — Eliquis alone brought in more than $14 billion last year.
- Plenge, who joined with the $74 billion Celgene acquisition in 2019, will stay on in an advisory role through March 2027 to help with the transition.
- Bristol Myers Squibb research chief Robert Plenge is leaving, and chief medical officer Cristian Massacesi will lead a unified R&D unit from January 1.
- The shake-up comes as the drugmaker faces patent expirations for its blockbusters Opdivo and Eliquis from around 2028 — Eliquis alone brought in more than $14 billion last year.
- Plenge, who joined with the $74 billion Celgene acquisition in 2019, will stay on in an advisory role through March 2027 to help with the transition.
Bristol Myers Squibb research chief Robert Plenge is leaving, and chief medical officer Cristian Massacesi will lead a unified R&D unit from January 1. The shake-up comes as the drugmaker faces patent expirations for its blockbusters Opdivo and Eliquis from around 2028 — Eliquis alone brought in more than $14 billion last year. Plenge, who joined with the $74 billion Celgene acquisition in 2019, will stay on in an advisory role through March 2027 to help with the transition. Chief executive Christopher Boerner said bringing research and development together as one organisation would speed decisions and strengthen the pipeline.
Bristol Myers Squibb research chief Robert Plenge is leaving, and chief medical officer Cristian Massacesi will lead a unified R&D unit from January 1. The shake-up comes as the drugmaker faces patent expirations for its blockbusters Opdivo and Eliquis from around 2028 — Eliquis alone brought in more than $14 billion last year. Plenge, who joined with the $74 billion Celgene acquisition in 2019, will stay on in an advisory role through March 2027 to help with the transition. Chief executive Christopher Boerner said bringing research and development together as one organisation would speed decisions and strengthen the pipeline.
Bristol Myers Squibb research chief Robert Plenge is leaving, and chief medical officer Cristian Massacesi will lead a unified R&D unit from January 1. The shake-up comes as the drugmaker faces patent expirations for its blockbusters Opdivo and Eliquis from around 2028 — Eliquis alone brought in more than $14 billion last year. Plenge, who joined with the $74 billion Celgene acquisition in 2019, will stay on in an advisory role through March 2027 to help with the transition. Chief executive Christopher Boerner said bringing research and development together as one organisation would speed decisions and strengthen the pipeline.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।